ClinicalTrials.gov
public full text
Public Domain
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety Study of MGD009 in B7-H3-expressing Tumors#894828
- Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors#845405
- Study of LTC004 in Subjects With Advanced Malignant Tumors#802544
- Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors#807774
- A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors#917869
Record · ID 1031767
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive